MAP2K7 and acute lymphoblastic leukemia: Based on our previous findings that patients with T-ALL exhibit aberrant activation of MAP2K7 [9], we decided to investigate the anti-leukemic properties of MAP2K7 inhibition with 5Z7O in a panel of T-ALL cell lines using an EBV-transformed lymphoblastoid cell line (LCL) as a non-leukemic control.